CLPT
ClearPoint Neuro, Inc.
$15.06
-0.61 (-3.89%)
At close · Jul 16
Market Cap
$451.64M
Shares
29,989,563
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.06
Open$15.39
Day$14.96–15.80
52W$8.27–30.10
Avg vol 30d853K
Short int4.3M · 14.3% float · 2.8d
Short vol56%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
+4%
above
RSI (14)
43
neutral
MACD trend
Negative
52-week position
31%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
+6%
trailing
YTD return
+10%
this year
Relative strength
−3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $15 — 200d above 50d
Institutional flow
Accumulating
8 of 121 funds reported for Jun 30 · net +13.6K sh shares · +1 new
Insider flow
Distributing
Net -$308.1K over 90 days · 100% sells
Short interest
Falling
14.34% of float · ▼ -12.6% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
121 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+18%
Y/Y
Gross margin
61%
expanding
EPS growth
−29%
Y/Y
Free cash flow
$-24.4M
Balance sheet
$3.2M
net debt
Quant / Vol
risk profile
Volatility
104%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 13, 2026
Revenue
· 2026
Maintained
$52M – $56M
prior FY $36.97M
midpoint +46.1% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
31%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $15 › 200d $15 — 200d above 50d
Institutional flow
Accumulating
8 of 121 funds reported for Jun 30 · net +13.6K sh shares · +1 new
Insider flow
Distributing
Net -$308.1K over 90 days · 100% sells
Short interest
Falling
14.34% of float · ▼ -12.6% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
121 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $15 · 31%
52-wk high $30
vs 200-day avg +2%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Biologics and drug delivery growth | 26% | the fourth quarter of 2025 | — |
| Functional neurosurgery disposables growth | 23% | the fourth quarter of 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLPT
this stock
ClearPoint Neuro, Inc.
|
$451.64M | +10.1% | +17.8% | — | 14.3% |
|
ABT
Abbott Laboratories
|
$172.14B | -20.7% | +5.7% | 27.7 | 1.3% |
|
SYK
Stryker Corp
|
$126.97B | -5.5% | +11.2% | 38.3 | 1.8% |
|
MDT
Medtronic plc
|
$106.96B | -12.3% | +8.4% | 22.4 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.32B | -53.2% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLPT | -15.8% | +12.9% | +6.0% | -15.6% | +10.1% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -15.6% | +12.8% | -3.0% | -16.1% | +0.0% |